226 related articles for article (PubMed ID: 11785519)
1. How companies stall generics and keep themselves healthy.
Stolberg SG; Gerth J
N Y Times Web; 2000 Jul; ():A1, A14, A15. PubMed ID: 11785519
[No Abstract] [Full Text] [Related]
2. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
3. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
4. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
5. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
6. Patent watch.
Harrison C
Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
[No Abstract] [Full Text] [Related]
7. Are patent expirations the answer to improving patient adherence?
Klepser DG
Am J Manag Care; 2008 Dec; 14(12):787-8. PubMed ID: 19067495
[No Abstract] [Full Text] [Related]
8. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
9. Protect pharmaceutical innovation.
Musselwhite LW; Andrews J
Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
[No Abstract] [Full Text] [Related]
10. Drug companies and third world: a case study in neglect. Medicine merchants: a special report.
McNeil DG
N Y Times Web; 2000 May; ():A1,6. PubMed ID: 11873794
[No Abstract] [Full Text] [Related]
11. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
12. Intellectual property. Fixing the legal framework for pharmaceutical research.
Knowles SM
Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
[No Abstract] [Full Text] [Related]
13. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
14. Not taking, just borrowing: government use of patented drugs.
Ossorio PN
Am J Bioeth; 2002; 2(3):51-2. PubMed ID: 12230861
[No Abstract] [Full Text] [Related]
15. It is not unethical, though it is often unwise, to override patents.
Leventer H
Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
[No Abstract] [Full Text] [Related]
16. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
17. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
18. Pharmaceuticals and medical devices: cost savings. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals and medical devices: business practices.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
[No Abstract] [Full Text] [Related]
20. Intellectual property. Drug patents at the Supreme Court.
Hemphill CS; Sampat B
Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
[No Abstract] [Full Text] [Related]
[Next] [New Search]